“…The high-potency μ-opioid receptor agonist, fentanyl, is an important clinical analgesic that has adverse side effects, including ventilatory depression and the development of hyperalgesia (enhanced pain perception) upon repeated administration ( Scholz et al, 1996 ; Suzuki and El-Haddad, 2017 ; Armenian et al, 2018 ; Tyler and Guarnieri, 2023 ). In addition, although the systemic injection of fentanyl causes profound analgesia in rats, it also exerts adverse effects on ventilatory parameters, the alveolar–arterial (A-a) gradient (index of alveolar gas exchange), and arterial blood–gas chemistry ( Henderson et al, 2014 ; Baby et al, 2021 ; Jenkins et al, 2021 ; Getsy et al, 2022a ; Getsy et al, 2022b ; Seckler et al, 2022 ; Marchette et al, 2023 ). The roles of μ-, δ-, and κ-opioid receptors ( Trescott et al, 2008 ; Valentino and Volkow, 2018 ), cell-signaling/molecular mechanisms ( Al-Hasani and Bruchas, 2011 ; Shang and Filizola, 2015 ), and multiple sites of action of opioids ( May et al, 1989 ; Lalley, 2003 ; Vadivelu et al, 2011 ; Henderson et al, 2013 ; 2014 ; Baby et al, 2018 ; Birdsong and Williams, 2020 ; Rossi and Bodnar, 2021 ) have been extensively studied.…”